ClinicalTrials.gg
RecruitingNCT06787456Updated Sep 1, 2026

"Xijiang Project" Screening Cohort for NPC

An observational study in Nasopharyngeal Carcinoma (NPC) and Screening, sponsored by Ming-Yuan Chen. Recruiting at 1 site in China. Open to participants aged 30 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Ming-Yuan Chen · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000,000
Ages
30 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen — 10 open to participants now, 10 under way, 3 of them phase 3. Nasopharyngeal Carcinoma · Ming-Yuan Chen.

Started
2024
with 1 other
Observational
Only one
of the 10
Registered
4th of 10
by date

Among the 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen, this one is one of 2 that started in 2024, is the only observational one, and was the 4th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

10 of the 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 30 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen, or all of them as a file.
02

Study summary

The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and family history, dietary and lifestyle habits, and geographical environmental factors; a biobank of blood, tissue fluid, swabs, etc., for Epstein-Barr virus, tumors, and genetics; a clinical examination database including nasopharyngoscopy, imaging, pathology, and other examinations; and databases of Epstein-Barr virus and human genetic sequencing, etc.

Read the detailed description

This study aims to initiate a multicenter prospective nasopharyngeal carcinoma (NPC) screening cohort study around China, starting from regions with high incidence of NPC, to conduct a million-person-scale screening cohort study. Participants who meet the selection criteria will be included in the cohort. All participants will undergo an epidemiological information survey (including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information) through questionnaires, and various samples such as blood, tissue fluid, and throat swabs will be collected. Quantitative testing or genetic sequencing will be conducted on Epstein-Barr virus (EBV) (including EBV-related proteins, antibodies, EBV DNA quantification and sequence length, methylation levels, and next-generation sequencing), nasopharyngeal epithelial or tumor cells, etc., to establish, validate, optimize, and promote the optimal combination screening strategy for NPC; participants defined as high-risk of NPC by screening will undergo clinical nasopharyngoscopy and combined imaging and pathological examinations to confirm NPC patients and provide them with precise clinical treatment; regular follow-ups of the entire cohort will be conducted to study the risk factors and molecular mechanisms of NPC. The purpose of this study is to establish a comprehensive and integrated data platform, primarily based on the population from the South China, including an NPC epidemiological information database based on the gender, age, ethnicity, dietary and lifestyle habits, and geographical environmental factors, a biobank based on various samples and screening test results, and a clinical examination database based on nasopharyngoscopy, head and neck MRI, and a database for EB virus and human genetic sequencing information, etc., forming a multi-source heterogeneous, open, and shared data platform. Based on this data platform, basic scientific and clinical research on NPC will be conducted, including: developing, validating, and optimizing new NPC screening markers and their composite screening programs, clarifying the target population for the promotion of NPC composite screening programs; research study of the etiology and risk factors of NPC from genetic, ethnic, geographical, environmental, and lifestyle aspects, proposing a dynamic evolutionary molecular theory of NPC occurrence and development; exploring NPC prevention measures through lifestyle changes, vaccination interventions, and other methods; exploring new de-escalation clinical treatment plans for NPC, constructing new strategies for precise prevention and treatment of NPC such as minimally invasive surgical treatment and de-escalation of chemoradiotherapy, etc.

03

Conditions studied

  • Nasopharyngeal Carcinoma (NPC)
  • Screening

Keywords

  • Nasopharyngeal Carcinoma (NPC)
  • screening
  • Epstein-Barr virus
  • EBV DNA
  • EBV antibody
04

Who can participate

Ages eligible
30 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Residents with a definite native place, aged 30 and 69 years at screening, and capable of long-term cooperation with screening and follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Residents with a definite native place;
  • Aged 30 and 69 years at screening;
  • Capable of long-term cooperation with screening and follow-up.

Exclusion criteria

Exclusion Criteria:

  • Known severe cardiovascular, liver or kidney disease, or neuropsychiatric disorders;
  • History of previous malignant tumors;
  • Severe diseases or immunodeficiency;
  • Females with a positive pregnancy test at screening;
  • Inability to cooperate with the study due to psychological, social, family, and geographical reasons.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Screening cohort of nasopharyngeal carcinoma

    Population participating in nasopharyngeal carcinoma screening, aged between 30 and 69 years old.

    Diagnostic Test: EBV antibodies test · Diagnostic Test: EBV DNA test · Other: epidemiological information survey · Other: Clinical examinations for high-risk participants · Other: EBV and human genetic sequencing

Interventions

  • Diagnostic testEBV antibodies test

    Test for VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.

  • Diagnostic testEBV DNA test

    quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.

  • Otherepidemiological information survey

    epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.

  • OtherClinical examinations for high-risk participants

    nasopharyngoscopy, head and neck MRI.

  • OtherEBV and human genetic sequencing

    EB virus and human genetic sequencing for plasma, etc.

06

What researchers measure

Primary outcomes

  1. A data platform for an NPC screening cohort

    A data platform, including an NPC epidemiological information database based on the gender, age, ethnicity, dietary and lifestyle habits, and geographical environmental factors, a biobank based on various samples and screening test results, and a clinical examination database based on nasopharyngoscopy, head and neck MRI, and a database for EB virus and human genetic sequencing information.

    Time frame: At screening, 3 years and 10 years thereafter

Secondary outcomes

  1. Prevalence and incidence rate of nasopharyngeal carcinoma

    Endoscopy combined with or without biopsy is performed to evaluate the prevalence and rate of new cases of nasopharyngeal carcinoma, in a cohort study, and to identify the associated factors related with nasopharyngeal carcinoma.

    Time frame: At screening, 3 years and 10 years thereafter

  2. Nasopharyngeal Carcinoma Death Rates

    Nasopharyngeal Carcinoma deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

    Time frame: At screening, 3 years and 10 years thereafter

  3. Death Rates From All Causes

    Deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

    Time frame: At screening, 3 years and 10 years thereafter

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2035, 133 months after the start.

Of 52 observational studies under Nasopharyngeal Carcinoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 155. This study's planned 133 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 22, 2025
StartActual
Nov 14, 2024
Primary completionEst.
Dec 2035
CompletionEst.
Dec 2045
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06787456
Lead sponsor
Ming-Yuan Chen
Collaborators
Fifth Affiliated Hospital, Sun Yat-Sen University, Sun Yat-Sen University Cancer Center
Responsible party
Ming-Yuan Chen (Professior, Chief physician, Sun Yat-sen University) — Sponsor-investigator
First posted
Jan 22, 2025
Start date
Nov 14, 2024
Primary completion
Dec 2035 (estimated)
Completion
Dec 2045 (estimated)
Last update
Sep 1, 2026

Study contacts

Ming-yuan Chen, MD, PhD
Contact
chmingy@mail.sysu.edu.cn
86-13903052650
Jiong-lin Liang, MD
Contact
liangjl@sysucc.org.cn
86-13172018626
Ming-yuan Chen, MD, PhD
study chair · Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion